Softmax Co., Ltd. (Japan) AI Stock Analysis
Want to see JP:3671 full AI Analyst Report?
Softmax Co., Ltd. (Japan) (3671) AI Stock Analysis
Softmax Co., Ltd. (Japan)
(TSE/TYO:3671)
Softmax earns a middling score. Fundamentals are stable but deteriorating at the margin: the company stays profitable with excellent cash conversion and a growing equity base, yet a 22% revenue decline, margin compression, a 41% drop in operating cash flow and a near-doubling of debt point to a transitional and less certain period. Technicals compound the caution, with the price trading below every major moving average and momentum indicators (negative MACD, RSI near 20) confirming a sustained downtrend. Offsetting these risks, the valuation is attractive at a 12.2x P/E with a 3.64% dividend yield, offering a cushion if revenue stabilizes. Investors should watch for evidence that sales have bottomed and that the added leverage is being deployed productively before the outlook improves.
Softmax Co., Ltd. (Japan) (3671) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.58B
- Dividend Yield
- 4.31%
- Average Volume (3M)
- 23.91K
- Price to Earnings (P/E)
- 11.4
- Beta (1Y)
- 0.63
- Revenue Growth
- -4.63%
- EPS Growth
- -28.26%
- Country
- Japan
- Employees
- 230
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Softmax Co., Ltd. (Japan) Business Overview & Revenue Model
Company Description
Softmax Co., Ltd handles the complete spectrum of corporate system services, encompassing their development, commercialization, deployment, and ongoing support. A significant portion of their work is dedicated to creating advanced medical information...
Softmax Co., Ltd. (Japan) Financial Statement Overview
Summary
Blended view of the Income Statement (62), Balance Sheet (58) and Cash Flow (55) scores. Softmax remains consistently profitable with net income rising to ¥573 million and net margins steady at 8-9%, supported by near-perfect free cash flow conversion (99% of net income) and a light capex model. However, the trajectory has weakened: revenue fell 22% in FY2025, breaking a multi-year growth trend; gross margin compressed from 30.8% to 26.9%; operating cash flow dropped 41% to ¥389 million; and total debt nearly doubled to ¥2.5 billion, lifting debt-to-equity to 0.63 from 0.40. The growing equity base (¥3.9 billion) and historically solid ROE (13-16%) keep the profile sound, but the combination of shrinking revenue, weaker cash generation and rising leverage caps the score near the middle of the range.
Income Statement
62PositiveBalance Sheet
58NeutralCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.92B | 6.93B | 5.43B | 5.26B | 5.05B | 4.49B |
| Gross Profit | 1.82B | 1.86B | 1.66B | 1.55B | 1.43B | 1.44B |
| EBITDA | 693.86M | 784.12M | 702.47M | 621.88M | 571.83M | 612.45M |
| Net Income | 488.18M | 573.46M | 480.15M | 452.77M | 419.39M | 422.55M |
Balance Sheet | ||||||
| Total Assets | 8.63B | 9.13B | 7.54B | 6.72B | 6.55B | 5.76B |
| Cash, Cash Equivalents and Short-Term Investments | 2.71B | 3.12B | 3.45B | 2.92B | 2.85B | 2.76B |
| Total Debt | 2.21B | 2.48B | 1.41B | 1.33B | 1.35B | 1.38B |
| Total Liabilities | 4.64B | 5.20B | 4.02B | 3.50B | 3.61B | 3.14B |
| Stockholders Equity | 3.99B | 3.93B | 3.52B | 3.22B | 2.94B | 2.62B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 384.89M | 625.84M | 215.28M | 163.96M | 266.65M |
| Operating Cash Flow | 0 | 388.95M | 663.98M | 232.54M | 179.73M | 284.30M |
| Investing Cash Flow | 0 | -1.17B | -92.76M | -11.61M | -4.75M | -1.01M |
| Financing Cash Flow | 0 | 883.56M | -100.22M | -200.04M | -144.93M | -401.85M |
Softmax Co., Ltd. (Japan) Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3671, the sentiment is Negative. The current price of 232.00 is below the 20-day moving average (MA) of 267.50, below the 50-day MA of 291.70, and below the 200-day MA of 312.28, indicating a bearish trend. The MACD of -14.34 indicates Positive momentum. The RSI at 19.20 is Positive, neither overbought nor oversold. The STOCH value of 0.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3671.
Softmax Co., Ltd. (Japan) Peers Comparison
Overall Rating
JP:448372Outperform
JP:448058Neutral
JP:367157Neutral
JP:443854Neutral
JP:934153Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | JPY 232.67B | 30.67 | ― | 0.52% | 20.50% | 19.27% | |
| 58Neutral | JPY 56.52B | 32.49 | 11.30% | ― | 21.01% | 10.15% | |
| 57Neutral | JPY 5.84B | 11.43 | ― | 4.31% | -4.63% | -28.26% | |
| 54Neutral | JPY 2.16B | -4.75 | ― | ― | 34.13% | 35.54% | |
| 53Neutral | JPY 10.04B | 14.86 | ― | 5.41% | 46.39% | 12.53% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3671 | Softmax Co., Ltd. (Japan) | 232.00 | -85.02 | -26.82% | |
| JP:4480 | Medley, Inc. | 1780.00 | -870.00 | -32.83% | |
| JP:4438 | Welby Inc. | 257.00 | -38.00 | -12.88% | |
| JP:4483 | JMDC Inc. | 3440.00 | -759.57 | -18.09% | |
| JP:9341 | GENOVA Inc. | 555.00 | -7.50 | -1.33% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
